PFE Pfizer Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 9-month channel rising
Price is between the lines.
- 9-month channel
- US$27.36 – US$31.27 · rising, +13% a year
- Price in channel
- 80% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$31.27
- Turns bearish below
- US$27.36
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 8:28 AM ET (2 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (2/6) — no published call or alerts; levels below are for reference.
Buy at or below
US$28.00
level as at 11 Nov 2026
Our target
US$32.20
by 23 Dec 2026
Projected move
15.0%
gross, before costs
Price is between our buy and target.
Target: PFE's usual move size (15.0%), the best return per day on this path.
6 settled calls · 2 reached target (33.3%) · average best move 5.2%. See the full record.
- Upper line touches
- 2
- Lower line touches
- 4
- Fit confidence
- 60%
- Fitted
- 1 Nov 2026
Company information
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla
- Employees
- 75,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- 57/100
- Profitability
- 41/100
- Financial health
- 43/100
- Cash generation
- 66/100
Key statistics
- Market cap
- US$153.14B
- Enterprise value
- US$215.36B
- Beta
- 0.28
- Avg volume
- 39.98M
- Revenue per share
- 11.18
- Dividend yield
- 6.40%
- 52-week range
- 23.58-28.75
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 35.50
- PEG
- -0.59
- Price / sales
- 2.40
- Price / book
- 1.80
- EV / EBITDA
- 17.06
- Gross margin
- 71.32%
- Operating margin
- 25.08%
- Net margin
- 6.81%
- Current ratio
- 1.27
- Quick ratio
- 0.96
- Debt / equity
- 0.74
- Interest cover
- 5.92
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$62.58B | US$44.01B | US$15.44B | US$7.77B | US$1.36 |
| 2024 | US$63.63B | US$41.85B | US$16.48B | US$8.02B | US$1.41 |
| 2023 | US$59.55B | US$30.34B | US$5.29B | US$2.13B | US$0.37 |
| 2022 | US$100.33B | US$62.09B | US$37.55B | US$31.36B | US$5.47 |
| 2021 | US$81.29B | US$46.88B | US$20.79B | US$22.15B | US$3.88 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$208.16B | US$121.39B | US$86.48B |
| 2024 | US$213.40B | US$124.90B | US$88.20B |
| 2023 | US$226.50B | US$137.21B | US$89.01B |
| 2022 | US$197.21B | US$101.29B | US$95.66B |
| 2021 | US$181.48B | US$104.01B | US$77.20B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$11.71B | US$9.08B | US$7.75B |
| 2024 | US$12.74B | US$9.84B | US$8.05B |
| 2023 | US$8.70B | US$4.79B | US$2.17B |
| 2022 | US$29.27B | US$26.03B | US$31.40B |
| 2021 | US$32.58B | US$29.87B | US$22.46B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$3.12 | US$61.94B | 17 |
| 2026 | US$2.97 | US$62.10B | 14 |
| 2027 | US$2.87 | US$59.49B | 14 |
| 2028 | US$2.46 | US$54.66B | 6 |
| 2029 | US$2.36 | US$52.98B | 3 |
| 2030 | US$2.44 | US$53.37B | 2 |
Analyst view
- Target (mean)
- US$27.38
- Target (high)
- US$31.00
- Target (low)
- US$25.00
- Strong buy
- 0
- Buy
- 15
- Hold
- 23
- Sell
- 1
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.